Indian pharmaceutical company Bharat Biotech is pushing ahead with a plan to supply the U.S. with the COVID-19 vaccine ‘Nose Vaccine’ developed for inoculations under the age of 18.
The vaccine has recently been approved for emergency use by the WHO and the World Health Organization, and has been recognized for its safety and reliability.
According to the Times of India on the 6th, OQGen, the US partner of Barat Biotech, announced the day before that it had applied to the US Food and Drug Administration for emergency use of a nasal vaccine for 2 to 18 year olds.
Ocugen found that the efficacy of a test conducted in India on 526 people aged 2 to 18 years and 25,800 adults aged 18 years and older were similar.
Unlike Pfizer and Moderna vaccines, which are manufactured using mRNA (messenger ribonucleic acid), the nasal vaccine was made in a traditional way using an inactivated virus like existing infant vaccines such as polio vaccine.
Earlier, the Indian government approved emergency use in January this year, when a phase 3 clinical trial of a nasal vaccine was in progress, and there was a ‘spontaneous approval controversy’.
India is expected to produce 300-320 million doses of vaccine per month by early next year.
(Photo = Getty Images Korea)